Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration

Louise A Ouattara, Andrea R Thurman, Terry A Jacot, Mackenzie Cottrell, Craig Sykes, Kimberly Blake, Xi Fang, Susan Ju, Nikolas C Vann, Jill Schwartz, Gustavo F Doncel, Louise A Ouattara, Andrea R Thurman, Terry A Jacot, Mackenzie Cottrell, Craig Sykes, Kimberly Blake, Xi Fang, Susan Ju, Nikolas C Vann, Jill Schwartz, Gustavo F Doncel

Abstract

Objective: To describe and compare systemic and local pharmacokinetics (PK) and cervicovaginal (CV) pharmacodynamics (PD) of oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC) with tenofovir (TFV) intravaginal ring (IVR).

Design: Phase I, randomized, parallel-group study. Women (n = 22) used TDF/FTC oral tablets daily or TFV IVR continuously and were assessed at baseline and 14 days.

Methods: TFV and FTC concentrations were measured in plasma, CV fluid (CVF), and CV tissue. TFV-diphosphate and FTC-triphosphate were assessed in CV tissue. In vitro PD antiviral activities of TFV and FTC (using in vivo concentration ranges) were modeled in the CVF and by infecting CV tissue explants ex vivo with HIV-1BaL.

Results: Adverse events (AEs) were more common with oral TDF/FTC use (P < 0.01). The median CVF TFV concentrations were 106 ng/mL after use of TFV IVR vs. 102 ng/mL for TDF/FTC. The median TFV and TFV-diphosphate concentrations in CV tissue were >100-fold higher among IVR users. The median CVF FTC concentrations were 103 ng/mL. FTC and FTC-triphosphate were detected in all CV tissues from TDF/FTC users. HIV inhibitory activity of CVF increased significantly with treatment in both cohorts (P < 0.01) but was higher in TFV IVR users (P < 0.01). In vitro inhibition of tissue infection with ex vivo administration of TFV and FTC was dose dependent, with maximal efficacy achieved with 10 µg/mL TFV, 1 µg/mL FTC, and 0.1 µg/mL of TFV and FTC combined.

Conclusions: Both products were safe and increased mucosal HIV inhibitory activity. In addition to systemic protection, oral TDF/FTC displays a PK/PD profile compatible with CV mucosal antiviral activity. TFV IVR resulted in fewer AEs, lower TFV plasma concentrations, higher CVF and tissue TFV and TFV-DP concentrations, and greater anti-HIV activity in CVF.

Trial registration: ClinicalTrials.gov NCT02722343 NCT02904369.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Figures

FIGURE 1.
FIGURE 1.
CONRAD A15-140 flow diagram.
FIGURE 2.
FIGURE 2.
A, Inhibition of HIV by ectocervical and vaginal fluids. B, CVF inhibition of HIV change from baseline.
FIGURE 3.
FIGURE 3.
A, p24 CUMULATIVE vs. treatment. B, p24 explants AUC vs. treatment.

References

    1. United Nations. Global AIDS Update 2018Miles to Go: Closing Gaps, Breaking Barriers, Righting Injustices. Available at: . 2018. Accessed January 10, 2021.
    1. Baeten JM, Donnell D, Ndase P, et al. . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
    1. Grant RM, Lama JR, Anderson PL, et al. . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434.
    1. Riddell Jt, Amico KR, Mayer KH. HIV preexposure prophylaxis: a Review. JAMA. 2018;319:1261–1268.
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.
    1. Van Damme L, Corneli A, Ahmed K, et al. . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
    1. Marrazzo J, Rabe L, Kelly C, et al. . Association of tenofovir (TFV) detection with reduced risk of herpes simplex virus type-2 (HSV-2) acquisition in the VOICE (MTN 003) study. AIDS Res Hum Retroviruses. 2014;30(suppl 1):A31.
    1. Delany-Moretlwe S, Lombard C, Baron D, et al. . Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18:1241–1250.
    1. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release. 2005;103:301–313.
    1. Alexander NJ, Baker E, Kaptein M, et al. . Why consider vaginal drug administration? Fertil Steril. 2004;82:1–12.
    1. Nel A, Kapiga S, Bekker LG, et al. . Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in AFrican Women. Vol. 2016. Boston, MA: CROI; 2016.
    1. Baeten JM, Palanee-Phillips T, Brown ER, et al. . Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
    1. Thurman AR, Clark MR, Hurlburt JA, et al. . Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health. 2013;5:695–708.
    1. Nel A, van Niekerk N, Kapiga S, et al. . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–2143.
    1. Clark JT, Clark MR, Shelke NB, et al. . Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One. 2014;9:e88509.
    1. Thurman AR, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PloS One. 2018;13:e0199778.
    1. Koetsawang S, Ji G, Krishna U, et al. . Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World health organization. Task force on long-acting systemic agents for fertility regulation. Contraception. 1990;41:125–141.
    1. Montgomery ET, van der Straten A, Cheng H, et al. . Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav. 2012;16:1787–1798.
    1. Smith DJ, Wakasiaka S, Hoang TD, et al. . An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt). 2008;17:1025–1034.
    1. Anderson PL, Glidden DV, Liu A, et al. . Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
    1. Hendrix CW, Andrade A, Bumpus NN, et al. . Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses 2016;32:32–43.
    1. Patterson KB, Prince HA, Kraft E, et al. . Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112re114.
    1. Donnell D, Baeten JM, Bumpus NN, et al. . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340–348.
    1. Johnson TJ, Clark MR, Albright TH, et al. . A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012;56:6272–6283.
    1. Wei X, Decker JM, Liu H, et al. . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–1905.
    1. Thurman AR, Schwartz JL, Cottrell ML, et al. . Safety and pharmacokinetics of a tenofovir alafenamide fumarate-emtricitabine based oral antiretroviral regimen for prevention of HIV acquisition in women: a randomized controlled trial. EClinicalMedicine. 2021;36:100893.
    1. Richardson-Harman N, Hendrix CW, Bumpus NN, et al. . Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PloS One. 2014;9:e111507.
    1. Richardson-Harman N, Lackman-Smith C, Fletcher PS, et al. . Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol. 2009;47:3530–3539.
    1. Jacot TA, Clark MR, Adedipe OE, et al. . Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies. Clin Transl Med. 2018;7:37.
    1. VØlund A. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Biometrics. 1978:357–365.
    1. Prinz H. Hill coefficients, dose–response curves and allosteric mechanisms. J Chem Biol. 2010;3:37–44.
    1. Karim SS, Kashuba AD, Werner L, et al. . Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279–281.
    1. Louissaint NA, Cao YJ, Skipper PL, et al. . Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013;29:1443–1450.
    1. Cottrell ML, Yang KH, Prince HM, et al. . A translational Pharmacology approach to predicting outcomes of preexposure prophylaxis Against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis.. 2016;214:55–64.
    1. Schwartz JL, Rountree RW, Kashuba ADM, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6:e25974.
    1. Thurman AR, Chandra N, Yousefieh N, et al. . Differences in local and systemic TFV PK among premenopausal versus postmenopausal women exposed to TFV 1% vaginal gel. J Acquir Immune Defic Syndr. 2018;78:82–92.
    1. Hendrix CW, Chen BA, Guddera V, et al. . MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PloS one. 2013;8:e55013.
    1. Herold BC, Chen BA, Salata RA, et al. . Impact of sex on the pharmacokinetics and pharmacodynamics of 1% tenofovir gel. Clin Infect Dis. 2016;62:375–382.
    1. Thurman AR, Schwartz JL, Brache V, et al. . Effect of hormonal contraception on pharmacokinetics of vaginal tenofovir in healthy women: increased tenofovir diphosphate in injectable depot medroxyprogesterone acetate users. J Acquir Immune Defic Syndr. 2019;80:79–88.
    1. Dobard C, Sharma S, Martin A, et al. . Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol. 2011;86:718–725.
    1. Parikh UM, Dobard C, Sharma S, et al. . Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83:10358–10365.
    1. Kashuba AD, Gengiah TN, Werner L, et al. . Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial: importance of adherence for microbicide effectiveness. J Acquir Immune Defic Syndr. 2015;69:264–269.
    1. Thurman AR, Schwartz JL, Ravel J, et al. . Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLoS One. 2019;14:e0217229.
    1. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med. 2011;62:127–139.
    1. Borroto-Esoda K, Vela JE, Myrick F, et al. . In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377–384.
    1. Ouattara A, Clark M, Doncel G, et al. . HIVR4P 2016 Conference. In: Time of Addition Studies of Elvitegravir/TFV Prodrug combinations Demonstrate Extended Window of prophylactic Activity in Cell and tissue Models. Vol. P08.01. Chicago, IL; 2016.
    1. Dumond JB, Yeh RF, Patterson KB, et al. . Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21:1899–1907.
    1. Clark MR, Friend DR. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res Hum Retroviruses. 2012;28:1458–1466.
    1. Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. . Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med. 2015;373:530–539.
    1. Andrei G, Lisco A, Vanpouille C, et al. . Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe. 2011;10:379–389.
    1. Thurman A, Schwartz JL, Brache V, et al. . The effect of hormonal contraception on pharmacokinetics of vaginal tenofovir in healthy women: increased tenofovir diphosphate in injectable depot medroxyprogesterone acetate users. J Acquir Immune Defic Syndr. 2018;80:79–88.
    1. Mensch BS, Brown ER, Liu K, et al. . Reporting of adherence in the VOICE trial: did disclosure of product nonuse increase at the termination visit? AIDS Behav. 2016;20:2654–2661.
    1. Mngadi KT, Maarschalk S, Grobler AC, et al. . Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014;18:849–854.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel